R&D Systems货号293-VE-010重组人VEGF

R&D Systems货号293-VE-010重组人VEGF 165上海睿安生物13611631389

Background:VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF₁₆₅ appears to be the most abundant and potent isoform, followed by VEGF₁₂₁ and VEGF₁₈₉ (3, 4). Isoforms other than VEGF₁₂₁ contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF₁₆₅ shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF₁₆₅ binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 9).

Due to its role in angiogenesis of blood vessels, tumor and stroma cells use VEGF to stimulate formation of blood vessels and the proliferation and survival of endothelial cells. Specific immunotherapies targeting the VEGF signaling pathway include the recombinant antibody against VEGF (Bevacizumab), antibodies targeting the main VEGF receptor (VEGFR2), and small molecule inhibitors against VEGF receptor tyrosine kinases (10). Immune checkpoint inhibitors are an important tool in cancer therapies as tumor cells can hijack immune checkpoint signals to evade detection by immune cells. In addition to stimulating the formation of tumor blood vessels, VEGF has immunosuppressive effects by acting on dendritic cells to block their antigen-presenting and T cell stimulatory functions. Targeting VEGF in combination with other immune checkpoint ligands or receptors may prove more effective in immunotherapy approaches to certain cancer types (11). Because of its role in the formation of blood vessels, VEGF is also an important factor in skeletal development where blood supply and vascularization are crucial. This has made VEGF an important molecule in regenerative studies for bone repair as sustained release of VEGF has been shown to improve the efficiency of bone regeneration (12).

In differentiation protocols for stems cells, VEGF is a commonly added growth factor for the transformation of induced pluripotent stem cells into hematopoietic progenitor cells used to make Natural Killer cells (13, 14). VEGF has also been used to transform intermediate mesoderm into kidney glomerular podocytes or stem cell-derived liver spheres (15, 16). VEGF may also be used in assistance of stem cell transplantations by supporting angiogenesis at sites of stem cell transplants or as a honing tool for adipose-derived mesenchymal stem cells or bone marrow stem cells to migrate to (17, 18).-

References:

1. Leung, D.W. et al. (1989) Science 246:1306.
2. Keck, P.J. et al. (1989) Science 246:1309.
3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
5. Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
6. Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
7. Thurston, G. (2002) J. Anat. 200:575.
8. Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
9. Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.
10. Apte, R.S. et al. (2019) Cell 176(6):1248.
11. Sangro, B. et al. (2021) Nature 18:525-543.
12. Hu, K. & Olsen, B.R. (2016) Bone 91:30-38.
13. Zhou, Y. et al. (2022) Cancers 14:2266.
14. Li, Y. et al. (2018) Cell Stem Cell 23(2):181-192.
15. Musah, S. et al. (2018) Nat. Protoc. 13(7):1662-1685.
16. Meseguer-Ripolles, J. et al. (2021) STAR Protoc. 2(2):100502.
17. Hutchings, G. et al. (2020) Int. J. Mol. Sci. 21(11):3790.
18. Zhang, W. et al. (2014) Euro Cell and Mater. 27:1-12.

产品种类丰富，质量稳定可靠.
R&D总公司于1976年成立于美国，在美国NASDAQ上市(TECH)。公司一直致力于各种细胞因子及其相关分子的生产研发。R&D的产品覆盖面广，种类丰富，质量稳定可靠，其生产的各种ELISA试剂盒、重组因子及抗体以其卓越的品质赢得了世界各国科研及临床诊断机构的青睐。
订购信息：

睿安公司专业技术服务
荧光定量PCR、甲基化检测、文库构建、原核和真核蛋白表达、高通量测序、抗体定制服务、WB检测、IHC检测。
睿安公司代理及优势品牌：
免疫学：Abgent、CST、R&D、Abcam、BD、Epitomics、Santa cruz、Jackson
耗材类： Ammex、Fisher、Bioplastics、Axygen、Corning、Greiner，Nunc-Nalgene
分子和细胞：Fermentas、hyclone-pierce、Qiagen、Bio-Rad
综合类： Sigma、 MERCK、Millipore、Roche、Invitrogen
自主品牌：Rainbio 生化类：Sigma-Vetec 、 MP
肥胖代谢类：Biovendor、ALPCO
表观遗传：Zymo ACTIVE MOTIF 神经和信号传导：Tocris
其他类： Biovision、Biocolor、Covance、Cytoskeleton、ebioscience、GE、Genetex、Invivogen、Omega、
Proteintech 、Socorex 、Vector